High-dose-rate brachytherapy boost for XXXX : comparison of two different fractionation schemes.

@entity1 @entity263 @entity1168
PURPOSE: This is a retrospective study comparing our experience with @entity1168 ( @entity1168 ) brachytherapy boost for @entity263 , using two different fractionation schemes, 600 cGy   3 fractions ( @entity1 group 1) and 950 cGy   2 fractions ( @entity1 group 2). METHODS AND MATERIALS: A total of 165 @entity1 were treated for @entity263 using external beam radiation therapy up to a dose of 45 Gy, followed by an @entity1168 brachytherapy prostate radiation boost. Between July 1997 and Nov 1999, 64 @entity1 were treated with an @entity1168 boost of 600 cGy   3 fractions; and between June 2000 and Nov 2005, 101 @entity1 were treated with an @entity1168 boost of 950 cGy   2 fractions. All but 9 @entity1 had at least one of the following risk features: pretreatment prostate-specific antigen (PSA) level >10, a Gleason score >= 7, and/or clinical stage T3 disease. RESULTS: Median follow-up was 105 months for group 1 and 43 months for group 2. @entity1 in group 2 had a greater number of high-risk features than group 1 (p = 0.02). Adjusted for comparable follow-up, there was no difference in biochemical no-evidence-of-disease (bNED) rate between the two fractionation scheme approaches, with 5-year Kaplan-Meier estimates of 93.5% in group 1 and 87.3% in group 2 (p = 0.19). The 5-year estimates of progression-free survival were 86% for group 1 and 83% for group 2 (p = 0.53). Among high-risk @entity1 , there were no differences in bNED or PFS rate due to fractionation. CONCLUSIONS: Results were excellent for both groups. Adjusted for comparable follow-up, no differences were found between groups.
